comparemela.com

Latest Breaking News On - Dainippon sumitomo pharma - Page 5 : comparemela.com

Epilepsy Market Registers 14 5% CAGR with Impressive Growth Opportunities During the Study Period [2017-2030], Ascertains DelveInsight

Epilepsy Market Registers 14 5% CAGR with Impressive Growth Opportunities During the Study Period [2017-2030], Ascertains DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Bill Yelle | UMass Lowell

Biosketch Bill Yelle has over 30 years of experience in the biopharmaceutical industry, ranging from large pharma to early stage, venture-backed companies. He currently serves as an Entrepreneur in Residence at Partners Innovation Fund (PIF) as well as an Adjunct Faculty Member at The Manning School of Business at UMass Lowell.  Before joining PIF, Bill was Executive Chairman of Envisia Therapeutics, as well as an advisor to several entrepreneurial startups. Prior to Envisia, Bill served as CEO of Aldea Pharmaceuticals, where he successfully completed a Series B raise and brought two programs into the clinic. Prior to Aldea, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.), where he was responsible for the consummation of over 30 material transactions, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. 

Japanese Offices in US Host Healthcare Tech and Digital Health Startup Business Opportunity Webinar for Expansion to Japan

SEATTLE, Wash., Feb 01, 2021 (SEND2PRESS NEWSWIRE) The Hyogo Business & Cultural Center and the Kobe Trade Information Office today announced the hosting of a webinar for Healthcare Tech and Digital Health startups looking for opportunities to expand their business into Japan. The webinar will be the first of its kind, with the goal of connecting with and providing useful information to as many potential future business partners as possible. The market for Digital Health/Health Tech is continuing to expand in Japan and with the effects of COVID-19, their importance has become a popular topic of conversation. Japanese pharma and insurance companies have also been proactively developing the market through joint business and investment with overseas startups. Japan has been putting more effort into inviting overseas startups to Japan. Also, municipalities who are proactive about receiving foreign investment are offering various forms of support.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.